Cargando…

Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2

The creation of safe and effective vaccines that induce potent cellular and humoral immune responses against SARS-CoV-2 is urgently needed to end the global COVID-19 epidemic. Here, we developed an alphavirus-derived self-replicating RNA (repRNA)-based vaccine platform encoding the receptor-binding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Guibin, Yan, Huan, Sun, Jing, Zhao, Jincun, Zhang, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122567/ https://www.ncbi.nlm.nih.gov/pubmed/37151990 http://dx.doi.org/10.1016/j.omtn.2023.04.021

Ejemplares similares

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
por: Liang, Qingtai, et al.
Publicado: (2022)

The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice
por: Sun, Wenqiang, et al.
Publicado: (2021)

Correction to “Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys”
por: Li, Heng, et al.
Publicado: (2021)

A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages
por: Zhang, Xiantao, et al.
Publicado: (2023)

A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice
por: Tokunoh, Nagisa, et al.
Publicado: (2023)

Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern
por: Tostanoski, Lisa H., et al.
Publicado: (2021)

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection
por: Olivera-Ugarte, Santa-Mariela, et al.
Publicado: (2022)

A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations
por: Kim, Seong A., et al.
Publicado: (2022)

Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
por: An, Xingyue, et al.
Publicado: (2021)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2
por: Pettini, Elena, et al.
Publicado: (2022)

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
por: Ma, Xiancai, et al.
Publicado: (2020)

564. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
por: Joyce, M G, et al.
Publicado: (2021)

mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates
por: Waickman, Adam T., et al.
Publicado: (2022)

Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
por: Kim, David S., et al.
Publicado: (2020)

An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response
por: Chen, Li, et al.
Publicado: (2022)

Comparison of replicating and nonreplicating vaccines against SARS-CoV-2
por: Mudrick, Haley E., et al.
Publicado: (2022)

Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses
por: Powers, John M., et al.
Publicado: (2021)

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
por: Liu, Jinyan, et al.
Publicado: (2022)

SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
por: Canedo-Marroquín, Gisela, et al.
Publicado: (2020)

Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization
por: Chiba, Shiho, et al.
Publicado: (2021)

Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection
por: Liu, Jiaojiao, et al.
Publicado: (2021)

Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2
por: Stewart, Erica L., et al.
Publicado: (2022)

Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses
por: Ouyang, Maggie Jing, et al.
Publicado: (2023)

A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
por: Pishesha, Novalia, et al.
Publicado: (2021)

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
por: He, Qian, et al.
Publicado: (2022)

Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine
por: Fan, Shengtao, et al.
Publicado: (2021)

Baculovirus-expressed self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induce protective immunity in mice
por: Liu, Xingjian, et al.
Publicado: (2023)

A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice
por: de Alwis, Ruklanthi, et al.
Publicado: (2021)

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
por: Zang, Jinkai, et al.
Publicado: (2021)

Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework
por: Kumar, Neeraj, et al.
Publicado: (2021)

Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity
por: Amano, Tomokazu, et al.
Publicado: (2023)

Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
por: Scaglione, Antonella, et al.
Publicado: (2021)

Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
por: Scaglione, Antonella, et al.
Publicado: (2021)

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
por: Walls, Alexandra C., et al.
Publicado: (2020)

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
por: Walls, Alexandra C., et al.
Publicado: (2020)

SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
por: Garrido, Carolina, et al.
Publicado: (2021)

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
por: Wang, Zijun, et al.
Publicado: (2022)

BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and Andes orthohantavirus
por: Soto, Jorge A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ebjnth9444ap9rl8pcsrelqhab